Quaranta Sylvie, Dupouey Julien, Colle Romain, Verstuyft Céline
Service de pharmacocinétique et toxicologie, laboratoire de biologie médicale, CHU Timone, Assistance publique-Hôpitaux de Marseille, 13000 Marseille, France.
Service de pharmacologie UF0598, CNRS, INT, institut neurosciences Timone, CHU Timone, Assistance publique-Hôpitaux de Marseille, Aix-Marseille université, 13000 Marseille, France.
Therapie. 2017 Apr;72(2):311-318. doi: 10.1016/j.therap.2016.09.018. Epub 2017 Jan 30.
Tailoring antidepressant drug therapy to each individual patient is a complex process because these drugs have adverse effects leading to discontinuation. Pharmacogenetics may provide useful information in routine practice for optimizing antidepressant treatment by helping limit toxic effects while maintaining efficacy. This review presents the usefulness of pharmacogenetic tests for P450 cytochromes CYP2C19 and CYP2D6 in psychiatric patients taking antidepressants. Depending on the level of evidence, the French National Network of Pharmacogenetics (RNPGx) has issued recommendations stating that pharmacogenetic tests for CYP2D6 and CYP2C19 genes are potentially useful in psychiatric patients treated with antidepressant drugs.
为每个患者量身定制抗抑郁药物治疗是一个复杂的过程，因为这些药物会产生导致停药的不良反应。药物遗传学可以通过在维持疗效的同时帮助限制毒性作用，为优化抗抑郁治疗的常规实践提供有用信息。本综述介绍了细胞色素P450 2C19（CYP2C19）和2D6（CYP2D6）的药物遗传学检测在服用抗抑郁药的精神科患者中的作用。根据证据水平，法国国家药物遗传学网络（RNPGx）发布了相关建议，指出针对CYP2D6和CYP2C19基因的药物遗传学检测在接受抗抑郁药物治疗的精神科患者中可能有用。
